In our study, we employed a network pharmacology approach to prioritize seven predicted targets (AKT1, VEGFA, EGFR, SRC, MAPK3, MMP9, MAPK1) of baicalein for asthma treatment, and confirmed its high binding affinity to these targets through molecular docking. Here, MAPK3 is linked to asthma.